Xinglong Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xinglong Fan has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Cuixia Chen
State Key Laboratory of Heavy Oil Processing and Center for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, China
4 shared publications Qilong Gu
State Key Laboratory of Heavy Oil Processing and Center for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, China
3 shared publicationsHai Xu
State Key Laboratory of Heavy Oil Processing and Centre for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, China
2 shared publicationsTiantian Liang
State Key Laboratory of Heavy Oil Processing and Centre for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, China
2 shared publicationsChao Sun
Department of Clinical Translational Medicine, YuceBio Technology Co., Ltd., Shenzhen 518000, China
1 shared publicationChen Wang
State Key Laboratory of Heavy Oil Processing and Centre for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, China
1 shared publication
Latest Publications
- 6 May 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 266, 115774
Glycine linker modulates the tunable self-assembly and antibacterial efficacy of octanoyl lipopeptides
- 6 May 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 266, 115774
Glycine linker modulates the tunable self-assembly and antibacterial efficacy of octanoyl lipopeptides
- 21 May 2024
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 40 (22) , 11806-11816
Antibiofilm Mechanisms of the Helical G3 Peptide against Staphylococcus epidermidis
Antibacterial peptides (ABPs) have been recognized as promising alternatives to conventional antibiotics due to their broad antibacterial spectrum, high antibacterial activity, and low possibility of inducing bacterial resistance. However, their antibiofilm mechanisms have not yet reached a consensus. In this study, we investigated the antibiofilm activity of a short helical peptide G3 against Staphylococcus epidermidis, one of the most important strains of medical device contamination. Studies show that G3 inhibits S. epidermidis biofilm formation in a variety of ways. In the initial adhesion stage, G3 changes the properties of bacterial surfaces, such as charges, hydrophobicity, and permeability, by rapidly binding to them, thus interfering with their initial adhesion. In the mature stage, G3 prefers to target extracellular polysaccharides, leading to the death of outside bacteria and the disruption of the three-dimensional (3D) architecture of the bacterial biofilm. Such efficient antibiofilm activity of G3 endows it with great potential in the treatment of infections induced by the S. epidermidis biofilm.
- 21 May 2024
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 40 (22) , 11806-11816
Antibiofilm Mechanisms of the Helical G3 Peptide against Staphylococcus epidermidis
Antibacterial peptides (ABPs) have been recognized as promising alternatives to conventional antibiotics due to their broad antibacterial spectrum, high antibacterial activity, and low possibility of inducing bacterial resistance. However, their antibiofilm mechanisms have not yet reached a consensus. In this study, we investigated the antibiofilm activity of a short helical peptide G3 against Staphylococcus epidermidis, one of the most important strains of medical device contamination. Studies show that G3 inhibits S. epidermidis biofilm formation in a variety of ways. In the initial adhesion stage, G3 changes the properties of bacterial surfaces, such as charges, hydrophobicity, and permeability, by rapidly binding to them, thus interfering with their initial adhesion. In the mature stage, G3 prefers to target extracellular polysaccharides, leading to the death of outside bacteria and the disruption of the three-dimensional (3D) architecture of the bacterial biofilm. Such efficient antibiofilm activity of G3 endows it with great potential in the treatment of infections induced by the S. epidermidis biofilm.
- 2 June 2023
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 649, 535-546
Disassembling ability of lipopeptide promotes the antibacterial activity
- 2 June 2023
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 649, 535-546
Disassembling ability of lipopeptide promotes the antibacterial activity
- 22 February 2023
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 640, 498-509
Amyloid-like aggregates of short self-assembly peptide selectively induce melanoma cell apoptosis
- 22 February 2023
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 640, 498-509
Amyloid-like aggregates of short self-assembly peptide selectively induce melanoma cell apoptosis
- Open Access
- 27 July 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-20
Genomic and Immunological Characterization of Pyroptosis in Lung Adenocarcinoma
Pyroptosis is a programmed cell death that may either promote or hinder cancer growth under different circumstances. Pyroptosis-related genes (PRGs) could be a useful target for cancer therapy, and are uncommon in lung adenocarcinoma (LUAD). The expression profiles, mutation data and clinical information of LUAD patients were included in this study. A pyroptosis-related prognostic risk score (PPRS) model was constructed by performing Cox regression, weighted gene co-expression network analysis (WGCNA), and least absolute shrinkage and selection operator (LASSO) analysis to score LUAD patients. Somatic mutation and copy number variation (CNV), tumor immunity, and sensitivity to immunotherapy/chemotherapy were compared between different PPRS groups. Clinical parameters of LUAD were combined with PPRS to construct a decision tree and nomogram. Red module was highly positively correlated with pyroptosis. Seven genes (FCRLB, COTL1, GNG10, CASP4, DOK1, CCR2, and AQP8) were screened from the red module to construct a PPRS model. Significantly lower overall survival (OS), higher incidence of somatic mutation and CNV, elevated infiltration level of the immune cell together with increased probability of immune escape were observed in LUAD patients with higher PPRS, and were more sensitive to Cisplatin, Docetaxel, and Vinorelbine. We constructed a new PPRS model for patients with LUAD. The model might have clinical significance in the prediction of the prognosis of patients with LUAD and in the efficacy of chemotherapy and immunotherapy.
- 27 July 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-20
Open AccessGenomic and Immunological Characterization of Pyroptosis in Lung Adenocarcinoma
Pyroptosis is a programmed cell death that may either promote or hinder cancer growth under different circumstances. Pyroptosis-related genes (PRGs) could be a useful target for cancer therapy, and are uncommon in lung adenocarcinoma (LUAD). The expression profiles, mutation data and clinical information of LUAD patients were included in this study. A pyroptosis-related prognostic risk score (PPRS) model was constructed by performing Cox regression, weighted gene co-expression network analysis (WGCNA), and least absolute shrinkage and selection operator (LASSO) analysis to score LUAD patients. Somatic mutation and copy number variation (CNV), tumor immunity, and sensitivity to immunotherapy/chemotherapy were compared between different PPRS groups. Clinical parameters of LUAD were combined with PPRS to construct a decision tree and nomogram. Red module was highly positively correlated with pyroptosis. Seven genes (FCRLB, COTL1, GNG10, CASP4, DOK1, CCR2, and AQP8) were screened from the red module to construct a PPRS model. Significantly lower overall survival (OS), higher incidence of somatic mutation and CNV, elevated infiltration level of the immune cell together with increased probability of immune escape were observed in LUAD patients with higher PPRS, and were more sensitive to Cisplatin, Docetaxel, and Vinorelbine. We constructed a new PPRS model for patients with LUAD. The model might have clinical significance in the prediction of the prognosis of patients with LUAD and in the efficacy of chemotherapy and immunotherapy.
- Open Access
- 15 February 2022
- Published by Springer Nature in Research Square
Postoperative Adjuvant Treatment Options in Resected Non–Small-Cell Lung Cancer
Lung cancer remains the most common malignancies and the leading cause of mortality worldwide, more than 80% of which are Non–Small-Cell Lung Cancer (NSCLC). For approximately one-third of diagnosed NSCLCs with stage I–IIIA disease, surgical resection is recommended as a preferred curative treatment. Nevertheless, many resected NSCLC patients experience recurrence. The adjuvant treatment option of patients with resected Non–Small-Cell Lung Cancer (NSCLC) remains unstandardized. At present, there are many postoperative adjuvant therapy options for resected NSCLC, including chemotherapy, targeted therapy, chemotherapy and immunotherapy. However, which adjuvant therapy is better for which patients is remaining to be explored. With further development of ctDNA-based molecular residual disease (MRD) research, more accurate clinical trials may be needed in the future to refine more comparison of biomarker for more precise treatment in postoperative adjuvant therapy in the future. In our manuscript, we discussed the status of possible markers and possible future clinical trials in combination with MRD. Finer patient stratification and adjuvant treatment options need to be further explored.
- 15 February 2022
- Published by Springer Nature in Research Square
Open AccessPostoperative Adjuvant Treatment Options in Resected Non–Small-Cell Lung Cancer
Lung cancer remains the most common malignancies and the leading cause of mortality worldwide, more than 80% of which are Non–Small-Cell Lung Cancer (NSCLC). For approximately one-third of diagnosed NSCLCs with stage I–IIIA disease, surgical resection is recommended as a preferred curative treatment. Nevertheless, many resected NSCLC patients experience recurrence. The adjuvant treatment option of patients with resected Non–Small-Cell Lung Cancer (NSCLC) remains unstandardized. At present, there are many postoperative adjuvant therapy options for resected NSCLC, including chemotherapy, targeted therapy, chemotherapy and immunotherapy. However, which adjuvant therapy is better for which patients is remaining to be explored. With further development of ctDNA-based molecular residual disease (MRD) research, more accurate clinical trials may be needed in the future to refine more comparison of biomarker for more precise treatment in postoperative adjuvant therapy in the future. In our manuscript, we discussed the status of possible markers and possible future clinical trials in combination with MRD. Finer patient stratification and adjuvant treatment options need to be further explored.